bluebird bio, Inc.

MUN:BLE Stock Report

Market Cap: €68.7m

bluebird bio Valuation

Is BLE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BLE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BLE (€0.33) is trading below our estimate of fair value (€8.35)

Significantly Below Fair Value: BLE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLE?

Key metric: As BLE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BLE. This is calculated by dividing BLE's market cap by their current revenue.
What is BLE's PS Ratio?
PS Ratio1.4x
SalesUS$53.12m
Market CapUS$71.94m

Price to Sales Ratio vs Peers

How does BLE's PS Ratio compare to its peers?

The above table shows the PS ratio for BLE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6x
2INV 2invest
8.2xn/a€63.2m
HPHA Heidelberg Pharma
12.6x16.6%€106.7m
MDG1 Medigene
2.8x13.3%€20.6m
CNW co.don
0.7xn/a€6.5m
BLE bluebird bio
1.4x41.5%€71.9m

Price-To-Sales vs Peers: BLE is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (7.8x).

Price to Sales Ratio vs Industry

How does BLE's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.7.9x21.8%
BLE bluebird bio
 1.4x41.5%US$71.94m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
BLE 1.4xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.7.9x42.4%
BLE bluebird bio
 1.4x49.0%US$71.94m
No more companies

Price-To-Sales vs Industry: BLE is good value based on its Price-To-Sales Ratio (1.4x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is BLE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: BLE is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BLE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.33
€2.23
+567.6%
77.5%€5.67€0.47n/a7
Nov ’25€0.47
€2.46
+427.6%
62.2%€5.37€0.89n/a8
Oct ’25€0.47
€2.46
+421.0%
62.2%€5.37€0.89n/a8
Sep ’25€0.56
€2.61
+369.8%
58.7%€5.44€0.91n/a8
Aug ’25€1.02
€3.47
+240.0%
64.5%€7.35€0.92n/a9
Jul ’25€0.89
€3.51
+294.1%
62.9%€7.41€0.93n/a11
Jun ’25€0.87
€3.51
+301.7%
62.9%€7.41€0.93n/a11
May ’25€0.86
€3.81
+343.1%
60.3%€7.50€0.94n/a12
Apr ’25€1.23
€3.90
+216.2%
59.3%€7.39€0.92n/a12
Mar ’25€1.31
€4.40
+236.9%
38.3%€7.40€1.85n/a11
Feb ’25n/a
€4.40
0%
38.3%€7.40€1.85n/a11
Jan ’25€1.23
€4.21
+242.5%
37.9%€7.27€1.82n/a10
Dec ’24€3.58
€6.72
+87.8%
40.3%€12.14€2.80n/a12
Nov ’24n/a
€6.62
0%
34.4%€10.25€2.80€0.4712
Oct ’24n/a
€6.62
0%
34.4%€10.25€2.80€0.4712
Sep ’24€3.31
€6.77
+104.8%
32.4%€10.12€2.76€0.5611
Aug ’24n/a
€6.49
0%
30.5%€8.93€2.68€1.0211
Jul ’24€2.96
€6.45
+118.4%
29.1%€9.10€2.73€0.8911
Jun ’24n/a
€6.51
0%
29.8%€9.29€2.79€0.8711
May ’24€4.10
€6.10
+49.0%
31.7%€9.08€2.72€0.8611
Apr ’24n/a
€6.23
0%
30.7%€9.17€3.67€1.2310
Mar ’24n/a
€6.73
0%
26.5%€9.18€3.67€1.319
Feb ’24n/a
€6.73
0%
26.5%€9.18€3.67n/a9
Jan ’24€6.49
€7.32
+12.8%
30.2%€9.98€2.99€1.239
Dec ’23€7.16
€7.32
+2.2%
30.2%€9.98€2.99€3.589
Nov ’23n/a
€7.65
0%
31.3%€10.13€3.04n/a9

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.55

7D

2.0%

1Y

95.6%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.20

7D

5.0%

1Y

23.7%

Pharming Group

€478.2m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

1.8%

1Y

-31.2%